Skip to content
  • Career
  • Support
  • Contact Us
Menu
  • Career
  • Support
  • Contact Us
  • Solutions
    • Clinical Services
    • Research Services
  • Get Started
    • Get Set Up
    • Get a Quote
  • Science
    • What We Do
    • How We Do It
    • Why It Matters
    • Our Core Areas
    • Technology
  • News & Events
    • News
    • Events
  • Resources
    • Webinars
    • Publications
    • Whitepapers
    • Report References
    • Media
  • About Us
    • About AMRA
    • The Team
    • Partners & Investors
Menu
  • Solutions
    • Clinical Services
    • Research Services
  • Get Started
    • Get Set Up
    • Get a Quote
  • Science
    • What We Do
    • How We Do It
    • Why It Matters
    • Our Core Areas
    • Technology
  • News & Events
    • News
    • Events
  • Resources
    • Webinars
    • Publications
    • Whitepapers
    • Report References
    • Media
  • About Us
    • About AMRA
    • The Team
    • Partners & Investors
Search
Close
Menu
  • Solutions
    • Clinical Services
    • Research Services
  • Get Started
    • Get a Quote
    • Get Set Up
  • News & Events
    • News
    • Events
  • Science
    • What We Do
    • How We Do It
    • Why It Matters
    • Our Core Areas
    • Technology
  • Resources
    • Webinars
    • Publications
    • Whitepapers
    • Report References
    • Media
  • About Us
    • About AMRA
    • The Team
    • Partners & Investors
  • Career
  • Support
  • Contact Us
  • All posts

AMRA Medical at AASLD 2022: Premier MRI Technology and Informatics for The Full Continuum of Liver Disease

AMRA Medical’s MRI-based technology and informatics are featured in seven abstracts accepted for presentation at The Liver Meeting 2022 – the world’s “must-attend” hepatology meeting.
  • October 26, 2022

Linköping, Sweden, October 26, 2022: AMRA Medical, and their collaborators, will present seven abstracts along the whole disease progression line of chronic liver disease, with studies involving individuals with early liver disease (non-alcoholic fatty liver disease; NAFLD) to cirrhosis to liver transplant. The data presented suggest that it may be possible to use the same objective, accurate, and precise magnetic resonance (MR)-based technology and informatics-based image analysis, to assess both physical frailty and sarcopenia throughout the course of disease. Those attending AASLD The Liver Meeting in November can learn more about how AMRA’s technology and informatics were used in these studies and how it all underpins our clinical applications, AMRA® MAsS Scan and AMRA® BCP Scan, by attending the abstract presentations or visiting AMRA’s exhibition booth #731.

AMRA’s magnetic resonance imaging (MRI)-based technology accurately measures various characteristics, such as muscle fat infiltration, muscle volume, and fat distribution, and objectively assesses muscle quality and quantity. The imaging-based technology and unique informatics platform can give insight into varying muscle phenotypes in different disease progression states, appealing to many internal and external research groups – from those investigating the biological nuances of liver disease to those developing the next generation of liver disease therapeutics and interventions. Such research has led to AMRA’s clinical offering which may assist clinicians with care decisions for liver patients.

Two abstracts involving individuals with early liver disease and the potential to risk stratify based on muscle composition will be presented. These include:

“Muscle composition, but not liver fat, predicts all-cause mortality in the UK Biobank imaging study​”

“Adverse muscle composition is a significant risk factor for all-cause mortality in NAFLD​”

Three abstracts — liver cirrhosis and two separate cohorts with liver transplant candidates — involving MR-based tests for assessing frailty and sarcopenia will be presented. These include:

“​Imaging-based test for physical frailty and sarcopenia – Interim results from the prospective cirrhosis cohort study ACCESS-ESLD​”

“Imaging-based test for sarcopenia – Interim results from a liver transplant waitlist natural history study​”

“Severity of Myosteatosis Correlates with Frailty in Patients with End-Stage Liver Disease​“

Two abstracts showing the utility of AMRA’s MR-based measurements of muscle and fat in liver transplant recipients will be presented. These include:

“​Randomized Controlled Trial of Low Calorie vs. Low Carbohydrate Diet on Metabophenotype in Liver Transplant Recipients with Obesity​”

“Relationship Between Metabophenotype and Atherogenic Lipoproteins in Liver Transplant Recipients ”

Considering all seven abstracts together — which spans different cohorts in Europe and USA, from early chronic disease to post-liver transplant — suggests AMRA’s technology is positioned to improve how researchers and clinicians stratify patients based on risk, evaluate various disease stages, and assess the effect of liver transplant on health outcomes or the effect of other interventions post-transplant.

Eric Converse, CEO of AMRA Medical commented: “We are so proud to see our years of research continue to help researchers develop more solutions for metabolic disorders such as liver disease. As part of our ambition to bring better healthcare to all, AMRA is excited to see our recently FDA-cleared AMRA® MAsS Scan being used to support clinical care decisions for patients with cirrhosis and those undergoing liver transplant. It’s empowering to see this technology, and also our FDA-cleared AMRA® BCP Scan which may help clinicians with disease prevention by providing actionable patient insights, make real-world impact. We’re hopeful our technology and services lessen the burden on healthcare providers by allowing patients to stay healthier longer.”

Converse continued: “I hope attendees are able to see our abstracts, attend the plenary session by Dr. Mohammad Siddiqui and then visit our booth to see how all this research has led to our amazing clinical decision-support applications for surgery such as liver transplant, chronic care such as cirrhotics and disease prevention.”

Attend the abstract presentations or visit our booth #731 to learn more about the utility of AMRA’s technology in liver disease research and in the clinic.

To contact us or read further about our clinical services visit our website and to find information about the abstracts, read more here.

  • All posts
Research Services
Follow us
Linkedin Twitter Facebook

About

AMRA offers clinical services and research services to support transformative care and vital decision-making, from clinical research to clinical care.

Contact

  • info@amramedical.com
  • +46 (0) 13 16 26 00
  • Contact Our Support
  • Data Privacy Policy
  • Cookie Policy
  • Data Privacy Policy
  • Cookie Policy

Newsletter

    © 2023 AMRA Medical AB

    AMRA Medical
    Manage Cookie Consent
    To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
    Functional Always active
    The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
    Preferences
    The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
    Statistics
    The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
    Marketing
    The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
    Manage options Manage services Manage vendors Read more about these purposes
    View preferences
    {title} {title} {title}
    AMRA Medical
    Manage Cookie Consent
    To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
    Functional Always active
    The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
    Preferences
    The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
    Statistics
    The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
    Marketing
    The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
    Manage options Manage services Manage vendors Read more about these purposes
    View preferences
    {title} {title} {title}